SK Biopharmaceuticals Co (XKRX:326030) Accounts Payable & Accrued Expense : ₩14,310 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is SK Biopharmaceuticals Co Accounts Payable & Accrued Expense?

SK Biopharmaceuticals Co's quarterly accounts payable & accrued expense declined from Sep. 2023 (₩16,170 Mil) to Dec. 2023 (₩2,435 Mil) but then increased from Dec. 2023 (₩2,435 Mil) to Mar. 2024 (₩14,310 Mil).

SK Biopharmaceuticals Co's annual accounts payable & accrued expense increased from Dec. 2021 (₩18,929 Mil) to Dec. 2022 (₩23,315 Mil) but then declined from Dec. 2022 (₩23,315 Mil) to Dec. 2023 (₩2,435 Mil).

SK Biopharmaceuticals Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for SK Biopharmaceuticals Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Biopharmaceuticals Co Accounts Payable & Accrued Expense Chart

SK Biopharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

8,953.61

18,928.85

23,314.68

2,434.58

SK Biopharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															16,141.36	10,769.02	16,169.85	2,434.58	14,310.37

SK Biopharmaceuticals Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

SK Biopharmaceuticals Co (XKRX:326030) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Biopharmaceuticals Co Ltd (XKRX:326030) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

221, Pangyoyeok-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbp.com

SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in research and development of new drugs for treatment of central nervous system (CNS) disorders. The company is also researching for the development of drugs to treat brain tumors, including metastatic tumors. It has a Bio Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Its drugs in pipeline include Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741.

SK Biopharmaceuticals Co (XKRX:326030) Headlines

No Headlines